An allogeneic first in class immunotherapy harnessing the patient immune system to fight immune tolerance and prevent cancer resistance
Phase I/II 1L mCRC study synopsis validated
Launch beg early 2024 (US, BEL, FR)
An allogeneic first in class immunotherapy harnessing the patient immune system to fight immune tolerance and prevent cancer resistance
Phase I/II 1L mCRC study synopsis validated
Launch beg early 2024 (US, BEL, FR)
High unmet need
2nd cause
of cancer mortality worldwide
608.000
Patients in 2029 WW
95%
of patients treated by chemotherapies in 1L inducing toxicity, resistances, and tumor plasticity.
Big Pharmas face a patent cliff
For Standard of care : Pembrolizumab, Atezolizumab, Nivolumab, Ipilimumab (within 2028)
Our product
Our response
01.
To meet the need in targeting treatment resistance
STC-1010 targets MSS and MSI-H population.
02.
To meet the need in breaking immunue tolerance
STC-1010 has a robust and validated preclinical data pack showing:
INCREASE IN OVERALL SURVIVAL
in colorectal cold and hot mice model
INCREASE IN CD8+ TUMOR INFILTRATION
in several model
EFFICACY IN ANTI-PD1 RESISTANT
mice model
03.
To meet the need for an accessible approach
An OFF-THE-SHELF technology allowing control of both time and cost of the manufacturing process.
Stc1010, the missing link ? A biological rational
Adapted from C. Cremolini ESMO 2021
Exemple of treatments with a biological rational to combine with STC 1010
Step 1
GM-CSF low dose: Recruits APC at injection point and mature DCs.
Step 2
Checkpoint inhibitors, ADC TLR Promotes T cell priming and activation
Step 3
Chemokyne cytokine TLR : Increase trafficking of T cell
Step 4
Bevacizumab Facilitates infiltration of CD8+ lymphocytes into tumors
Step 5
5FU, Bevacizumab and Cyclophosphamide low dose, radiotherapy. Decrease the activity of immunosuppressive cells (Tregs and MDSCs)
Step 6
Checkpoint inhibitors, ADC, BiSpecific mAb, TLR restores the anticancer immunity